TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer
Elbaz M, Ahirwar D, Xiaoli Z, Zhou X, Lustberg M, Nasser M, Shilo K, Ganju R. TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer. Oncotarget 2016, 9: 33459-33470. PMID: 30323891, PMCID: PMC6173360, DOI: 10.18632/oncotarget.9663.Peer-Reviewed Original ResearchTriple-negative breast cancerTransient receptor potential vanilloid type-2Negative breast cancerTNBC patientsTRPV2 expressionBreast cancerHigher recurrence-free survivalRecurrence-free survivalLimited therapeutic optionsGood prognostic markerEfficacy of chemotherapyNovel therapeutic strategiesNormal breast tissueMouse model studiesFree survivalNegative patientsAggressive diseaseTherapeutic optionsCancer patientsTNBC tumorsPrognostic markerTNBC tissuesTRPV2 activationNovel biomarkersTherapeutic strategies